Reporting adverse events in COVID-19 studies involving medicinal products to Lareb

28 May 2020

Lareb has approached the CCMO about the reporting of adverse events in COVID-19 studies involving medicinal products used for purposes other than those for which they were originally registered, such as chloroquine, hydroxychloroquine or azithromycin.

Bijwerkingencentrum Lareb plays an important role in collecting knowledge of side effects and sharing this knowledge. Lareb calls for reporting them of adverse events that occur in clinical studies and provides a simple table for this purpose in order to briefly record and share an adverse event (click here for the table). We bring this to your attention as you are an researcher of one or more COVID-19 studies. Lareb has a separate e-mail address for further questions regarding these reports: covid19@lareb.nl.